2024-07-05 14:35:06 ET
Summary
- Actinium Pharmaceuticals, Inc. is focused on developing radiolabeled biologics for blood cancer treatment, with a potential approval for Iomab-B by 2025.
- Positive late-stage data supports Iomab-B approval for relapsed/refractory AML patients, with a strong cash position to support the process.
- Uncertainty around approval timelines and lack of BLA submission has led to a decrease in Actinium Pharmaceuticals' valuation, presenting a potential investment opportunity.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Actinium Pharmaceuticals: Oversold Despite No Bad News